Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dolutegravir + abacavir
- Development stage
- Unknown
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dolutegravir + abacavir is a fixed-dose combination antiretroviral medication used for the treatment of HIV/AIDS. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the integration of viral DNA into the host genome by binding to the integrase active site and inhibiting the strand transfer step essential for HIV replication. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI), specifically a guanosine analogue, which interferes with HIV reverse transcription by inhibiting viral RNA-dependent DNA polymerase, thereby preventing replication of HIV. This combination reduces viral load and increases immune cell counts in people living with HIV but does not cure the infection[5][6][8].
- Brand names
- TriumeqTriumeq PD
- Other names
- abacavir + dolutegravir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseIntegrase allosteric pocket (HIV)
Beyond the preview
Go deeper on dolutegravir + abacavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dolutegravir + abacavir.